The cellular therapy also was generally well-tolerated, Adicet said.Ĭitius Pharmaceuticals ( CTXR) rose 8.3% after the oncology company said it has completed enrollment for a phase III study of its I/ONTAK drug candidate for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. In company news, Adicet Bio ( ACET) surged more than 30% after announcing interim data from phase I testing of its ADI-001 investigational CAR-T therapy in patients with B-cell non-Hodgkin's lymphoma, with two of the four evaluable patients showing a complete response to the treatment and another having a partial response. The Nasdaq Biotechnology index, however, was down 1.4%. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 1.0% while the SPDR Health Care Select Sector ETF (XLV) was up 0.6%. Institutional Distribution Intelligence. Non-Traditional Exchanges & New Markets.Directors’ and Officers’ Questionnaires.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |